Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Keros Therapeutics's net current asset value per share for the quarter that ended in Jun. 2026 was $12.19.
The historical rank and industry rank for Keros Therapeutics's Net Current Asset Value or its related term are showing as below:
KROS'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.59 Med: 4.15 Max: 6.29
Current: 0.91
During the past 8 years, the highest Price-to-Net-Current-Asset-Value Ratio of Keros Therapeutics was 6.29. The lowest was 0.59. And the median was 4.15.
KROS's Price-to-Net-Current-Asset-Value is ranked better than 93.86% of 929
companies
in the Biotechnology industry
Industry Median: 4.79
vs KROS: 0.91
Keros Therapeutics (NAS:KROS) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Keros Therapeutics Net Current Asset Value Related Terms
Keros Therapeutics Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Keros Therapeutics's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KROS vs VYGR, CHRS, DTIL: Net Current Asset Value Comparison
For the Biotechnology subindustry, Keros Therapeutics's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Keros Therapeutics Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Keros Therapeutics's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Keros Therapeutics's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $12.19 mean?
Keros Therapeutics (KROS) has a Net Current Asset Value of $12.19 as of Jun. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Keros Therapeutics and its competitors. According to the industry distribution chart, Keros Therapeutics ranks #57 out of 929 companies in the Biotechnology industry, placing it in the top 6.1%.
Is Keros Therapeutics' Net Current Asset Value too high?
Keros Therapeutics' current Net Current Asset Value is $12.19. The Biotechnology industry median Net Current Asset Value is 4.79. Keros Therapeutics' value of $12.19 is 154.5% above this industry median. Based on the distribution chart, Keros Therapeutics ranks #57 out of 929 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Keros Therapeutics has a GF Score™ of 51/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Keros Therapeutics' Net Current Asset Value compare to VYGR and CHRS?
According to the Biotechnology industry distribution chart, Keros Therapeutics ranks #57 out of 929 companies for Net Current Asset Value. This places Keros Therapeutics in the top 6% of its industry — outperforming the majority of peers. The industry median Net Current Asset Value is 4.79. Keros Therapeutics' value of $12.19 is 154.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.79, based on 929 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Keros Therapeutics's current Net Current Asset Value of $12.19 is 154.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Keros Therapeutics and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Keros Therapeutics's current Net Current Asset Value is $12.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Keros Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Keros Therapeutics (KROS) is currently considered Fairly Valued. The stock's GF Value™ is $10.10, compared to a current price of $11.08 — trading 9.7% above its estimated fair value. The current Net Current Asset Value is $12.19 and 154.5% above the Biotechnology industry median of 4.79. Keros Therapeutics' overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Keros Therapeutics (KROS), the current Net Current Asset Value is $12.19 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Keros Therapeutics (KROS) Overvalued in 2026?
Based on GuruFocus' analysis, Keros Therapeutics stock appears to be overvalued.
The current stock price of $11.08 is trading 9.7% above its estimated GF Value™ of $10.10.
GuruFocus considers Keros Therapeutics to be Fairly Valued.
Key valuation signals for KROS:
Net Current Asset Value: $12.19
GF Value™: $10.10 vs. price of $11.08 (9.7% above fair value)
Industry Position: 154.5% above the Biotechnology median (#57 of 929)
No single metric tells the full story. See the KROS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
51GF Score
Get the complete analysis for KROS
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KROS has been successfully added to your 
